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Background: The start of chemotherapy usually requires a delay of about 4 weeks after surgical resection of
colorectal cancer. However, there is no evidence for the required length of this delay interval. In addition, there is a
chance that a patient may die because postoperative chemotherapy was not started soon enough and a metastatic
tumor was able to develop rapidly. We therefore conducted a pilot study to determine the safety and feasibility of
an early start of chemotherapy after the resection of colorectal cancer with distant metastases.
Methods: Five patients were enrolled. They received XELOX therapy (130 mg/m2 of oxaliplatin on day 1 plus
1,000 mg/m2 of capecitabine twice daily on days 1 to 14) on the 7th postoperative day and XELOX + bevacizumab
(7.5 mg/kg of bevacizumab on day 1) after the 2nd cycle of chemotherapy.
Results: Five patients underwent open surgery. The procedures included right hemicolectomy in 1 patient,
sigmoidectomy in 2 patients, high anterior resection in 1 patient, and Hartmann procedure in 1 patient. All patients
started chemotherapy on postoperative day 7. The median number of cycles of chemotherapy was 11 (8 to 22). No
postoperative complications were observed. The tumor reduction rate was 44.3% (32.0 to 66.6%). Progression-free
survival was 10.3 months.
Conclusions: An early start of chemotherapy after surgery is feasible and safe. These findings suggest possible
changes in the start time of chemotherapy after surgery in the future. We have already started a new phase II trial
to confirm the effects of the early start of chemotherapy after surgery.
Trial registration: UMIN000004361.
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The surgical resection of asymptomatic primary colorectal
cancer (CRC) with unresectable synchronous metastases
is controversial. There are no doubts that among patients
with severe intestinal symptoms, resection is mandatory
before starting systemic chemotherapy [1-3]. The palliative
resection of the primary tumor has also been reported to
improve the efficacy of systemic chemotherapy [4] and
prolong the duration of chemotherapy [5]. A recent review
article suggested that non-curative resection of asympto-
matic colorectal primary tumors may prolong survival in* Correspondence: yy4160@yahoo.co.jp
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reproduction in any medium, provided the orpatients with metastatic CRC [6]. However, another article
concluded that initial chemotherapy should be started
with resection of the primary tumor reserved for the small
proportion of patients who develop major complications
from the primary tumor because resection of an asymp-
tomatic primary tumor provides only minimal palliative
benefits [7].
The purpose of the surgical resection of primary tumors
is the prevention of hemorrhage, perforation, and bowel
obstruction. In many cases, it is not possible for patients
to continue chemotherapy treatments because of compli-
cations, such as bleeding, perforation, and bowel obstruc-
tion, after chemotherapy is started without surgical
resection of the primary tumor. Thus, it seems necessaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chemotherapy with few complications. However, surgical
resection may delay the start of chemotherapy [8]. Gene-
rally, an interval of 4 weeks is considered necessary after
an operation before beginning chemotherapy with treat-
ments such as folinic acid, fluorouracil (5-FU), and oxali-
platin (FOLFOX); folinic acid, 5-FU, and irinotecan
(FOLFIRI); and capecitabine and oxaliplatin (XELOX).
However, there is no apparent evidence for this delay. A
metastatic tumor can enlarge rapidly before the start of
chemotherapy and possibly lead to patient death. Because
the significance of the postoperative 4-week delay until
the start of chemotherapy is not clear, we evaluated the
feasibility and safety of an early start with chemotherapy
in patients who had undergone colorectal surgery for
CRC, and who had synchronous multiple distant metasta-
ses. This was a pilot study to exclude major problems with
early administration of chemotherapy, and a phase II trial
should be performed to confirm the safety and effects of
the early start of chemotherapy after surgery.Methods
This study was designed as a pilot trial that was aimed
at evaluating the feasibility of an early start of chemo-
therapy after surgery. After approval by our institutional
review board, five consecutive patients who had primary
CRC with synchronous distant metastases were enrolled.
Further eligibility criteria included the following: (1) age
20 to 75 years; (2) Eastern Cooperative Oncology Group
performance status of 0 or 1; (3) life expectancy of 3
months or more; (4) adequate hematological function
(absolute leukocyte count 4,000 to 12,000 leukocytes/
mm3; neutrophil count 2,000 neutrophils/mm3 or more,
and platelets 100,000 platelets/mm3 or more), hepatic
function (transaminases 2.5 times or less the upper limit
of normal, and serum bilirubin 2.0 mg/dL or less) and
renal function (serum creatinine below the upper limit
of normal), and (5) ability to take oral medication.
Patients were excluded if they had any of the following:
brain metastases, history of other neoplasms (except
cured non-melanoma skin carcinoma or cured carci-
noma in situ), history of severe drug allergies, interstitial
pneumonitis or pulmonary fibrosis, severe pleural effu-
sion or ascites, active infection, diarrhea, or serious
uncontrolled comorbidities or medical conditions.
Patients had received no prior chemotherapy. They
received XELOX therapy (130 mg/m2 of oxaliplatin on
day 1 plus 1,000 mg/m2 of capecitabine twice daily on
days 1 to 14) on postoperative day 7 and XELOX +
bevacizumab (7.5 mg/kg of bevacizumab and 130 mg/m2
of oxaliplatin on day 1 plus 1,000 mg/m2 of capecitabine
twice daily on days 1 to 14, every 3 weeks) after the se-
cond cycle of chemotherapy (Figure 1), [9].All patients underwent a physical examination, chest
radiography, and computed tomographic scans of the
abdomen, pelvis, and chest before starting treatment at
baseline. All patients were included in the safety and
efficacy analyses. The severity of the adverse effects was
evaluated according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC), version 4.0. Tumors
were measured at 6- to 8-week intervals, and response was
evaluated according to the response evaluation criteria for
solid tumors (RECIST), version 1.1. The evaluation of re-
sponse was based on radiologist-reported measurements.
Complete and partial response required subsequent con-
firmation of response after an interval of at least 4 weeks.
The primary endpoint was postoperative morbidity
within 30 postoperative days, and the secondary end-
points were response rate and progression-free survival
(PFS). The following postoperative complications were
predefined and prospectively measured: abdominal in-
fection, anastomosis leakage, abdominal bleeding, and
infection of the ileus or the wound. Other complications
were recorded as appropriate. Hospital mortality was
defined as postoperative death for any cause within 30
postoperative days, or death within the hospitalization
period. The trial is registered with UMIN (Registration
number, UMIN000004361). Written informed consent
was obtained from all patients in advance.
Results and discussion
This pilot study completed its accrual goal of five patients
between December 2010 and April 2011. The minimum
follow-up period was 12 months. Table 1 details the pa-
tient demographic and clinicopathological features. There
were five men male patients with a median age of 67 years
(range 50 to 72 years). All patients had tumors that were
almost completely obstructive, with stenosis preventing
the passage of the endoscope. Five patients underwent
open surgery. A right hemicolectomy was performed in
one patient, sigmoidectomy in two patients, a high ante-
rior resection without a protective stoma in one patient,
and a Hartmann procedure was performed in one patient.
The median operating time was 130 minutes (range 75 to
225 minutes), and estimated blood loss was 60 mL (range
15 to 229 mL). The two patients who underwent sigmoi-
dectomy had the longest operating times because of a
history of previous surgery. A protocol for enhanced re-
covery after surgery (ERAS) was not applied in these five
patients. All patients successfully started chemotherapy on
postoperative day 7. No patient experienced any surgical
complications within the first 7 postoperative days. The
median number of cycles of chemotherapy was 11 (range
8 to 22 cycles). The median tumor shrinkage was 44.3%
(range 32.0 to 66.6%). The response rate was 100%. The
PFS ranged from 7.4 to 14.9 months with a median of 10.3
months (Table 2).
Figure 1 XELOX plus bevacizumab regimen in the study. Patients received XELOX therapy on the postoperative day 7 and XELOX + bevacizumab
after the second cycle of chemotherapy.
Yoshida et al. World Journal of Surgical Oncology 2013, 11:39 Page 3 of 5
http://www.wjso.com/content/11/1/39During the postoperative period, no patient developed
surgical or medical complications due to the early start of
chemotherapy. No in-hospital mortality occurred. NCI-
CTC version 4.0 toxicity is described in Table 3. Two
patients had grade 2 thrombocytopenia. Grade 1 hand-foot
syndrome was observed in all patients. Grade 3 anorexia
was observed in one patient. All adverse events were iden-
tified after the first seven postoperative days. No patient
experienced other grade 3 or greater toxicities (Table 3).
No patient experienced grade 2 or greater surgical compli-
cations or the chemotherapy toxicities in the first 60 days
after colorectal surgery.
The National Comprehensive Cancer Network currently
recommends that patients with metastatic CRC undergo
surgical intervention if they have a bowel obstruction, an
impending obstruction, or metastases that are potentially
resectable. Complications from the primary lesion are
uncommon in these circumstances, and the removal of
the lesion delays the initiation of systemic chemotherapy.
Resection of CRC in patients with severe symptoms is
mandatory before starting chemotherapy. In the past,
some investigators have recommended routine resection
of the primary tumor in order to prevent the need for
urgent surgical procedures because of local complicationsTable 1 Baseline characteristics
Patient 1 Patient 2
Age 55 50
Gender Male Male
Primary tumor Sigmoid colon Ascending colon
Operation Sigmoidectomy Right colectomy
Operating time, minutes 145 75
Bleeding, mL 60 15
Metastatic site Liver Liver[1,2]. Ruo reported that 30 (29%) of the 103 patients who
were initially managed without bowel resection required a
subsequent operation for the palliation of complications
[10]. McCahill and Poultsides reported that only those
cases with complete obstruction, perforation or massive
bleeding (7 to 4%), require surgery of their primary tumor
[11,12]. However, there is no report about an early start of
chemotherapy after resection of primary CRC. Recently,
some authors have suggested the elective resection of
asymptomatic CRC in at least a subset of patients with less
advanced stage IV disease [3,10]. Furthermore, Faron et al.
reported the independent prognostic value on survival of
primary tumor resection in patients with CRC and unre-
sectable metastases [13]. Other authors have suggested
deferring the resection of minimally symptomatic colorec-
tal tumors because most of these patients succumb to
progressive systemic disease instead of the complications
related to the intact primary lesion [8,10,14]. We reported
on a case involving an early chemotherapy start in a
patient who had undergone right hemicolectomy for
synchronous multiple liver metastases [14]. He survived
for 22 months despite having huge liver metastases. We
started this prospective study to confirm the feasibility of
an early start of chemotherapy after surgery.Patient 3 Patient 4 Patient 5
67 72 72
Male Male Male
Rectum Rectum Sigmoid colon





Table 2 Efficacy of chemotherapy
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Start, POD 7 7 7 7 7
Cycles 22 12 11 8 10
Response, % 66.6 44.3 32.0 33.3 46.9
PFS, months 14.9 12.6 8.1 7.4 10.3
POD, postoperative day; PFS, progression-free survival.
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diate postoperative period. This is primarily due to the be-
lief that 5-FU will increase the anastomotic leakage rate.
This can result in the need for reoperation, the creation of
a colostomy, and the need for a future takedown, or even
death. It is estimated that one out of three postoperative
deaths after colonic surgery are due to a leaking anasto-
mosis [15]. The dangers of postoperative 5-FU have been
well documented. Several animal studies have documen-
ted a weaker anastomosis and the increased risk of anasto-
motic rupture when systemic 5-FU is given as a bolus
immediately postoperatively [16,17]. Immediate intraperi-
toneal 5-FU also increases the risk of anastomotic dehis-
cence [18]. It has been documented that the continuous
infusion of 5-FU allows for the use of greater daily dosages
and appears safer than bolus administration of 5-FU [19].
Continuous infusion avoids the high peak serum levels of
5-FU that are seen with bolus dosing and may be effective
for CRC without increasing the anastomotic leak rate. The
oral fluoropyrimidine, UFT, and capecitabine, which have
been developed to improve tolerability and patient con-
venience, have replaced the continuous infusion of 5-FU
in many treatment regimens [20]. Oral fluoropyrimidine is
a promising alternative to constant infusion of 5-FU, and
pharmacokinetic studies have found that consecutive oral
administration of UFT at 370 mg/m2/day given as tegafur,
provided a steady-state concentration of 5-FU that was
comparable to that achieved by a 5-day constant infusion
at 250 mg/m2/day. In addition, injecting a bolus of 5-FUTable 3 Adverse events during chemotherapy











Malaise Grade1 -results in ultra-high concentrations followed by rapid
disappearance [21,22]. Therefore, we chose the XELOX
regimen for this study.
Currently, the precise timing for starting treatment with
chemotherapeutic agents prior to and/or after surgery in
order to avoid postoperative complications is not clear,
but an interval of at least 4 weeks has been suggested. In
most clinical trials, patients who had undergone an ope-
ration within 4 weeks were excluded. In Benoist’s study,
the mean interval between diagnosis and the chemother-
apy start was 44 days in the resection group versus 15 days
in the chemotherapy group [8]. In our patients, although
the operation was performed, the median interval between
diagnosis and the chemotherapy start was 17 days. Re-
section of the primary tumor significantly increased the
hospital stay and delayed the initiation of chemotherapy;
however, there was no evidence to suggest that this delay
was associated with reduced response rates leading to
curative resection or reduced survival. However, there is a
chance that patients may die if they are not able to start
chemotherapy, because of the rapid postoperative progre-
ssion of a metastatic tumor [23,24].
ERAS protocols aim at reducing the surgical stress re-
sponse and optimizing recovery in order to reduce the
length of hospital stays [25]. All elements in ERAS have
separately been shown to improve patient outcome. Be-
cause ERAS was developed, an early start to chemother-
apy after surgery was enabled. Early chemotherapy after
surgery may therefore prevent tumor growth. Resection of
colorectal tumors that involve severe stenosis and bleeding
is the first treatment step in order to prevent complica-
tions related to these tumors. The European multicentre
study, the colon cancer laparoscopic or open resection
(COLOR) trial, aimed to assess the short-term and long-
term outcomes after laparoscopic or open surgery for
colon cancer [26,27]. Further early administration will be
made possible by minimally invasive surgery for the treat-
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surgery for colon cancer.
Conclusions
To the best of our knowledge, this is the first pilot study
to determine the feasibility of early chemotherapy after re-
section of primary CRC with distant metastases, albeit in a
small cohort of well-selected patients. An early start to
chemotherapy after surgery may be safe and may improve
the prognosis of CRC patients with synchronous metasta-
ses. These findings suggest possible changes in the future
to the time of starting chemotherapy after surgery. We
have already started a new phase II trial to confirm the
effects of the early start of chemotherapy after surgery.
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